Allergan to lose license in Canada to sell breast implants

|About: Allergan plc (AGN)|By:, SA News Editor

Subsequent to its assessment of textured breast implants, Health Canada has informed Allergan (AGN +1.9%) that it intends to suspend its marketing license for its Biocell line.

The regulator is taking action after being notified of 28 confirmed cases there of breast implant recipients developing anaplastic large cell lymphoma, 24 involving Biocell.

Subscribe for full text news in your inbox